Bropirimine immunotherapy of upper urinary tract carcinoma in situ

Michael F. Sarosdy, Louis L. Pisters, Peter R. Carroll, Mitchell C. Benson, Timothy D. Moon, Donald L. Lamm, M'liss A. Hudson, Seth P. Lerner, Michael Koch, Paul F. Schellhammer

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives. Bropirimine has been shown to be effective in treating approximately 50% of patients with carcinoma in situ (CIS) of the bladder in recent clinical trials. Patients with upper tract CIS were treated with bropirimine to determine whether this oral drug might be effective in that setting. Methods. Twenty-four patients with negative radiographic findings and positive cytologic evidence for upper tract CIS in one or both ureters received bropirimine (3.0 g/day orally) for 3 consecutive days each week for up to 1 year. Ureteral collection of urine or barbotage for cytologic analysis was performed quarterly thereafter. Results. Ten (48%) of 21 evaluable patients had a negative ureteral cytologic analysis after 12 weeks (5 patients) or 24 weeks (5 patients). Of these 10 patients, 8 continue to have negative cytology for a period of 3 to 30 months (median, more than 9 months). In 2 patients, negative cytology reverted to positive at 6 and 9 months, respectively, during therapy. Twelve (50%) of the 24 patients reported no toxicity. Three patients stopped treatment at 2, 2, and 3 weeks due to pruritic rash, nausea and vomiting, and severe bone pain, respectively. Therapy was stopped in 1 additional patient between 4 and 5 months because of transient liver enzyme elevations, yet this patient has had a continuous negative cytologic analysis for more than 9 months. Conclusions. Orally administered bropirimine may be an effective therapy for CIS of the ureter or renal pelvis, with acceptable toxicity in most patients. Further efforts to better define this activity as well as the possible need for maintenance or intermittent long-term therapy are warranted.

Original languageEnglish (US)
Pages (from-to)28-32
Number of pages5
JournalUrology
Volume48
Issue number1
DOIs
StatePublished - Jul 1996
Externally publishedYes

Fingerprint

Carcinoma in Situ
Urinary Tract
Immunotherapy
Ureter
bropirimine
Cell Biology
Therapeutics
Urine Specimen Collection
Kidney Pelvis
Exanthema
Nausea
Vomiting
Urinary Bladder
Maintenance
Clinical Trials

ASJC Scopus subject areas

  • Urology

Cite this

Sarosdy, M. F., Pisters, L. L., Carroll, P. R., Benson, M. C., Moon, T. D., Lamm, D. L., ... Schellhammer, P. F. (1996). Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology, 48(1), 28-32. https://doi.org/10.1016/S0090-4295(96)00080-5

Bropirimine immunotherapy of upper urinary tract carcinoma in situ. / Sarosdy, Michael F.; Pisters, Louis L.; Carroll, Peter R.; Benson, Mitchell C.; Moon, Timothy D.; Lamm, Donald L.; Hudson, M'liss A.; Lerner, Seth P.; Koch, Michael; Schellhammer, Paul F.

In: Urology, Vol. 48, No. 1, 07.1996, p. 28-32.

Research output: Contribution to journalArticle

Sarosdy, MF, Pisters, LL, Carroll, PR, Benson, MC, Moon, TD, Lamm, DL, Hudson, MA, Lerner, SP, Koch, M & Schellhammer, PF 1996, 'Bropirimine immunotherapy of upper urinary tract carcinoma in situ', Urology, vol. 48, no. 1, pp. 28-32. https://doi.org/10.1016/S0090-4295(96)00080-5
Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL et al. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 1996 Jul;48(1):28-32. https://doi.org/10.1016/S0090-4295(96)00080-5
Sarosdy, Michael F. ; Pisters, Louis L. ; Carroll, Peter R. ; Benson, Mitchell C. ; Moon, Timothy D. ; Lamm, Donald L. ; Hudson, M'liss A. ; Lerner, Seth P. ; Koch, Michael ; Schellhammer, Paul F. / Bropirimine immunotherapy of upper urinary tract carcinoma in situ. In: Urology. 1996 ; Vol. 48, No. 1. pp. 28-32.
@article{d633b79fa37c42088ab94ec27901171d,
title = "Bropirimine immunotherapy of upper urinary tract carcinoma in situ",
abstract = "Objectives. Bropirimine has been shown to be effective in treating approximately 50{\%} of patients with carcinoma in situ (CIS) of the bladder in recent clinical trials. Patients with upper tract CIS were treated with bropirimine to determine whether this oral drug might be effective in that setting. Methods. Twenty-four patients with negative radiographic findings and positive cytologic evidence for upper tract CIS in one or both ureters received bropirimine (3.0 g/day orally) for 3 consecutive days each week for up to 1 year. Ureteral collection of urine or barbotage for cytologic analysis was performed quarterly thereafter. Results. Ten (48{\%}) of 21 evaluable patients had a negative ureteral cytologic analysis after 12 weeks (5 patients) or 24 weeks (5 patients). Of these 10 patients, 8 continue to have negative cytology for a period of 3 to 30 months (median, more than 9 months). In 2 patients, negative cytology reverted to positive at 6 and 9 months, respectively, during therapy. Twelve (50{\%}) of the 24 patients reported no toxicity. Three patients stopped treatment at 2, 2, and 3 weeks due to pruritic rash, nausea and vomiting, and severe bone pain, respectively. Therapy was stopped in 1 additional patient between 4 and 5 months because of transient liver enzyme elevations, yet this patient has had a continuous negative cytologic analysis for more than 9 months. Conclusions. Orally administered bropirimine may be an effective therapy for CIS of the ureter or renal pelvis, with acceptable toxicity in most patients. Further efforts to better define this activity as well as the possible need for maintenance or intermittent long-term therapy are warranted.",
author = "Sarosdy, {Michael F.} and Pisters, {Louis L.} and Carroll, {Peter R.} and Benson, {Mitchell C.} and Moon, {Timothy D.} and Lamm, {Donald L.} and Hudson, {M'liss A.} and Lerner, {Seth P.} and Michael Koch and Schellhammer, {Paul F.}",
year = "1996",
month = "7",
doi = "10.1016/S0090-4295(96)00080-5",
language = "English (US)",
volume = "48",
pages = "28--32",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Bropirimine immunotherapy of upper urinary tract carcinoma in situ

AU - Sarosdy, Michael F.

AU - Pisters, Louis L.

AU - Carroll, Peter R.

AU - Benson, Mitchell C.

AU - Moon, Timothy D.

AU - Lamm, Donald L.

AU - Hudson, M'liss A.

AU - Lerner, Seth P.

AU - Koch, Michael

AU - Schellhammer, Paul F.

PY - 1996/7

Y1 - 1996/7

N2 - Objectives. Bropirimine has been shown to be effective in treating approximately 50% of patients with carcinoma in situ (CIS) of the bladder in recent clinical trials. Patients with upper tract CIS were treated with bropirimine to determine whether this oral drug might be effective in that setting. Methods. Twenty-four patients with negative radiographic findings and positive cytologic evidence for upper tract CIS in one or both ureters received bropirimine (3.0 g/day orally) for 3 consecutive days each week for up to 1 year. Ureteral collection of urine or barbotage for cytologic analysis was performed quarterly thereafter. Results. Ten (48%) of 21 evaluable patients had a negative ureteral cytologic analysis after 12 weeks (5 patients) or 24 weeks (5 patients). Of these 10 patients, 8 continue to have negative cytology for a period of 3 to 30 months (median, more than 9 months). In 2 patients, negative cytology reverted to positive at 6 and 9 months, respectively, during therapy. Twelve (50%) of the 24 patients reported no toxicity. Three patients stopped treatment at 2, 2, and 3 weeks due to pruritic rash, nausea and vomiting, and severe bone pain, respectively. Therapy was stopped in 1 additional patient between 4 and 5 months because of transient liver enzyme elevations, yet this patient has had a continuous negative cytologic analysis for more than 9 months. Conclusions. Orally administered bropirimine may be an effective therapy for CIS of the ureter or renal pelvis, with acceptable toxicity in most patients. Further efforts to better define this activity as well as the possible need for maintenance or intermittent long-term therapy are warranted.

AB - Objectives. Bropirimine has been shown to be effective in treating approximately 50% of patients with carcinoma in situ (CIS) of the bladder in recent clinical trials. Patients with upper tract CIS were treated with bropirimine to determine whether this oral drug might be effective in that setting. Methods. Twenty-four patients with negative radiographic findings and positive cytologic evidence for upper tract CIS in one or both ureters received bropirimine (3.0 g/day orally) for 3 consecutive days each week for up to 1 year. Ureteral collection of urine or barbotage for cytologic analysis was performed quarterly thereafter. Results. Ten (48%) of 21 evaluable patients had a negative ureteral cytologic analysis after 12 weeks (5 patients) or 24 weeks (5 patients). Of these 10 patients, 8 continue to have negative cytology for a period of 3 to 30 months (median, more than 9 months). In 2 patients, negative cytology reverted to positive at 6 and 9 months, respectively, during therapy. Twelve (50%) of the 24 patients reported no toxicity. Three patients stopped treatment at 2, 2, and 3 weeks due to pruritic rash, nausea and vomiting, and severe bone pain, respectively. Therapy was stopped in 1 additional patient between 4 and 5 months because of transient liver enzyme elevations, yet this patient has had a continuous negative cytologic analysis for more than 9 months. Conclusions. Orally administered bropirimine may be an effective therapy for CIS of the ureter or renal pelvis, with acceptable toxicity in most patients. Further efforts to better define this activity as well as the possible need for maintenance or intermittent long-term therapy are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0030200621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030200621&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00080-5

DO - 10.1016/S0090-4295(96)00080-5

M3 - Article

VL - 48

SP - 28

EP - 32

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -